{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T16:14:36Z","timestamp":1716567276376},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T00:00:00Z","timestamp":1524096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Mantle cell lymphoma (MCL) has the worst prognosis of B-cell subtypes owing to its aggressive clinical disease course and incurability with standard chemo-immunotherapy. Options for relapsed MCL are limited, although several single agents have been studied. Lenalidomide is available in Italy for patients with MCL based on a local disposition of the Italian Drug Agency.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Subjects, Materials, and Methods<\/jats:title>\n                  <jats:p>An observational retrospective study was conducted in 24 Italian hematology centers with the aim to improve information on effectiveness and safety of lenalidomide use in real practice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Seventy patients received lenalidomide for 21\/28 days with a median of eight cycles. At the end of therapy, there were 22 complete responses (31.4%), 11 partial responses, 6 stable diseases, and 31 progressions, with an overall response rate of 47.1%. Eighteen patients (22.9%) received lenalidomide in combination with either dexamethasone (n\u2009=\u200913) or rituximab (n\u2009=\u20095). Median overall survival (OS) was reached at 33 months and median disease-free survival (DFS) at 20 months: 14\/22 patients are in continuous complete response with a median of 26 months. Patients who received lenalidomide alone were compared with patients who received lenalidomide in combination: OS and DFS did not differ. Progression-free survivals are significantly different: at 56 months, 36% in the combination group versus 13% in patients who received lenalidomide alone. Toxicities were manageable, even if 17 of them led to an early drug discontinuation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Lenalidomide therapy for relapsed MCL patients is effective and tolerable even in a real-life context.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implication for Practice<\/jats:title>\n                  <jats:p>Several factors influence treatment choice in relapsed\/refractory mantle cell lymphoma (rrMCL), and the therapeutic scenario is continuously evolving. In fact, rrMCL became the first lymphoma for which four novel agents have been approved: temsirolimus, lenalidomide, ibrutinib, and bortezomib. The rrMCL therapeutic algorithm is not so well established because data in the everyday clinical practice are still poor. Lenalidomide for rrMCL patients is effective and tolerable even in a real-life context.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2017-0597","type":"journal-article","created":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T15:55:13Z","timestamp":1524153313000},"page":"1033-1038","source":"Crossref","is-referenced-by-count":3,"title":["Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study)"],"prefix":"10.1093","volume":"23","author":[{"given":"Vittorio","family":"Stefoni","sequence":"first","affiliation":[{"name":"Institute of Hematology, University of Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Pellegrini","sequence":"additional","affiliation":[{"name":"Institute of Hematology, University of Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Broccoli","sequence":"additional","affiliation":[{"name":"Institute of Hematology, University of Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Baldini","sequence":"additional","affiliation":[{"name":"Division of Hematology, Fondazione IRCCS Ospedale Maggiore Policlinico, Universit\u00e0 degli Studi di Milano, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Tani","sequence":"additional","affiliation":[{"name":"Unit of Hematology, Santa Maria delle Croci Hospital, Ravenna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Cencini","sequence":"additional","affiliation":[{"name":"Hematology Unit, University of Siena, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amalia","family":"Figuera","sequence":"additional","affiliation":[{"name":"Division of Hematology, AOU Policlinico-Vittorio Emanuele, Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Ansuinelli","sequence":"additional","affiliation":[{"name":"Hematology, Department of Cellular Biotechnologies and Hematology, \u2018Sapienza' University, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Bernocco","sequence":"additional","affiliation":[{"name":"Division of Hematology - SS. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Cantonetti","sequence":"additional","affiliation":[{"name":"UOC Onco-Hematology Policlinico Tor Vergata, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Christina","family":"Cox","sequence":"additional","affiliation":[{"name":"Hematology, Sant'Andrea Hospital, La Sapienza University, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Ballerini","sequence":"additional","affiliation":[{"name":"IRCCS A.O.U. San Martino-IST, Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Rusconi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Niguarda Cancer Center, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Visco","sequence":"additional","affiliation":[{"name":"Department of Cell Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Arcaini","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Fondazione IRCCS Policlinico San Matteo & Department of Molecular Medicine, University of Pavia, Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Fama","sequence":"additional","affiliation":[{"name":"Hematology-Arcispedale S.Maria Nuova IRCCS, Reggio Emilia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Marasca","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Section of Hematology, University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Volpetti","sequence":"additional","affiliation":[{"name":"Chair of Hematology, DRMM, University of Udine, Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Castellino","sequence":"additional","affiliation":[{"name":"A.O. Citt\u00e0 della Salute e della Scienza di Torino, Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catello","family":"Califano","sequence":"additional","affiliation":[{"name":"Onco-Ematologia Ospedale Pagandi, Salerno, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Cavaliere","sequence":"additional","affiliation":[{"name":"Medicine I and Hematology, San Paolo Hospital, Savona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Gini","sequence":"additional","affiliation":[{"name":"Affiliate Clinic of Hematology Ospedali Riuniti, Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Marina","family":"Liberati","sequence":"additional","affiliation":[{"name":"S.C. Onco-Ematologia, A.O.S. Maria di Terni, Terni, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo","family":"Musuraca","sequence":"additional","affiliation":[{"name":"Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRST, IRCCS, Meldola, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Lucania","sequence":"additional","affiliation":[{"name":"Hematology Unit, ASL Napoli 1 Centro, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"Ricciuti","sequence":"additional","affiliation":[{"name":"Department of Hematology, Lymphoma Unit, Spirito Santo Hospital, Pescara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Argnani","sequence":"additional","affiliation":[{"name":"Institute of Hematology, University of Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"Institute of Hematology, University of Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,4,19]]},"reference":[{"key":"2021122511124804500_onco12458-bib-0001","article-title":"Incidence and survival trends in mantle cell lymphoma","author":"Epperla","year":"2017","journal-title":"Br J Haematol"},{"key":"2021122511124804500_onco12458-bib-0002","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1182\/blood-2014-03-559930","article-title":"Real world data on primary treatment for mantle cell lymphoma: A Nordic Lymphoma Group observational study","volume":"124","author":"Abrahamsson","year":"2014","journal-title":"Blood"},{"issue":"suppl 4","key":"2021122511124804500_onco12458-bib-0003","doi-asserted-by":"crossref","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"key":"2021122511124804500_onco12458-bib-0004","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122511124804500_onco12458-bib-0005","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: Phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122511124804500_onco12458-bib-0006","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1093\/annonc\/mdt366","article-title":"Long-term follow-up of lenalidomide in relapsed\/refractory mantle cell lymphoma: Subset analysis of the NHL-003 study","volume":"24","author":"Zinzani","year":"2013","journal-title":"Ann Oncol"},{"key":"2021122511124804500_onco12458-bib-0007","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"2021122511124804500_onco12458-bib-0008","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122511124804500_onco12458-bib-0009","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122511124804500_onco12458-bib-0010"},{"key":"2021122511124804500_onco12458-bib-0011","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma","volume":"145","author":"Habermann","year":"2009","journal-title":"Br J Haematol"},{"key":"2021122511124804500_onco12458-bib-0012","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1470-2045(15)00559-8","article-title":"Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): A phase 2, randomised, multicentre trial","volume":"17","author":"Trneny","year":"2016","journal-title":"Lancet Oncol"},{"key":"2021122511124804500_onco12458-bib-0013","first-page":"4","article-title":"Impact of prior treatment on PFS for relapsed\/refractory mantle cell lymphoma patients randomized to lenalidomide vs investigator's choice: A subgroup analysis of the phase II MCL-002 (SPRINT) study","volume":"100","author":"Trneny","year":"2015","journal-title":"Haematologica"},{"key":"2021122511124804500_onco12458-bib-0014","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/bjh.12755","article-title":"Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma","volume":"165","author":"Tuscano","year":"2014","journal-title":"Br J Haematol"},{"key":"2021122511124804500_onco12458-bib-0015","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/leu.2013.95","article-title":"Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: A phase II clinical trial","volume":"27","author":"Wang","year":"2013","journal-title":"Leukemia"},{"key":"2021122511124804500_onco12458-bib-0016","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-14-2221","article-title":"Combination of lenalidomide and rituximab overcomes rituximab resistance in patients with indolent B-cell and mantle cell lymphomas","volume":"21","author":"Chong","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2021122511124804500_onco12458-bib-0017","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/cncr.28405","article-title":"Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas","volume":"120","author":"Ahmadi","year":"2014","journal-title":"Cancer"},{"key":"2021122511124804500_onco12458-bib-0018","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3324\/haematol.2011.051813","article-title":"Salvage treatment with lenalidomide and dexamethasone in relapsed\/refractory mantle cell lymphoma: Clinical results and effects on microenvironment and neo-angiogenic biomarkers","volume":"97","author":"Zaja","year":"2012","journal-title":"Haematologica"},{"key":"2021122511124804500_onco12458-bib-0019","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.3109\/10428194.2014.964702","article-title":"Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: An Italian observational multicenter retrospective study in daily clinical practice","volume":"56","author":"Zinzani","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"2021122511124804500_onco12458-bib-0020","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/10428194.2016.1184755","article-title":"The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: An Italian observational, multicenter, retrospective study","volume":"58","author":"Zinzani","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"2021122511124804500_onco12458-bib-0021","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122511124804500_onco12458-bib-0022","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13045-017-0537-5","article-title":"Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed\/progressed after or were refractory\/intolerant to ibrutinib (MCL-004)","volume":"10","author":"Wang","year":"2017","journal-title":"J Hematol Oncol"},{"key":"2021122511124804500_onco12458-bib-0023","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/hon.2380","article-title":"Predictive factors and outcomes for ibrutinib therapy in relapsed\/refractory mantle cell lymphoma-A \u201creal world\u201d study","volume":"35","author":"Epperla","year":"2017","journal-title":"Hematol Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2017-0597","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2017-0597","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/9\/1033\/41915738\/oncolo_23_9_1033.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/9\/1033\/41915738\/oncolo_23_9_1033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T11:13:36Z","timestamp":1640430816000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/23\/9\/1033\/6439698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,19]]},"references-count":23,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,4,19]]},"published-print":{"date-parts":[[2018,9,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0597","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,9,1]]},"published":{"date-parts":[[2018,4,19]]}}}